Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Formula:C58H72ClFN12O8SColor and Shape:SolidMolecular weight:1151.78MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Formula:C20H16F6N4O2SColor and Shape:SolidMolecular weight:490.422TL13-112
CAS:<p>TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).</p>Formula:C49H60ClN9O10SPurity:98%Color and Shape:SolidMolecular weight:1002.57DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Color and Shape:LiquidDD0-2363
<p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>Formula:C36H36ClFN6O4Color and Shape:SolidMolecular weight:671.16Syk-IN-4
<p>Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.</p>Color and Shape:SolidAD57 (hydrochloride)
CAS:<p>AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.</p>Formula:C22H21ClF3N7OPurity:98%Color and Shape:SolidMolecular weight:491.9Verucopeptin
CAS:<p>Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.</p>Formula:C43H73N7O13Color and Shape:SolidMolecular weight:896.08BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Formula:C27H29Cl2FN8O3Purity:99.11%Color and Shape:Odour SolidMolecular weight:603.47JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formula:C18H20F3N7OColor and Shape:SolidMolecular weight:407.401hCA/VEGFR-2-IN-4
<p>hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/</p>Formula:C22H23FN6O5SPurity:98%Color and Shape:SolidMolecular weight:502.52TL13-12
CAS:<p>TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).</p>Formula:C45H53ClN10O10SPurity:98%Color and Shape:SolidMolecular weight:961.49PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Formula:C49H51N11O8Purity:98%Color and Shape:SolidMolecular weight:922VEGFR2/HDAC1-IN-1
<p>VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.</p>Purity:98%Color and Shape:Odour SolidTrastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Color and Shape:Odour LiquidAngiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Color and Shape:Odour SolidEGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Formula:C68H84N12O9Purity:98%Color and Shape:SolidMolecular weight:1213.47AD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurity:99.05%Color and Shape:SoildMolecular weight:455.44BCR-ABL-IN-3
CAS:<p>BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.</p>Formula:C20H17ClF2N4O3SColor and Shape:SolidMolecular weight:466.89
